论文部分内容阅读
目的 评价血必净辅助治疗脓毒血症的临床效果。方法将同期收治的46例脓毒血症患者随机分为治疗组26例和对照组20例,两组均予常规治疗,在此基础上观察组加用血必净注射液。观察两组入院时及治疗7 d后C反应蛋白(CRP)、APACHEⅡ评分及病死率。结果治疗7 d后两组各项指标均较入院时显著改善,其中观察组血清CRP水平、APACHEⅡ评分及病死率显著低于对照组(P<0.05)。结果血必净注射液能对脓毒血症发病的多项环节起阻断作用,明显降低其病死率,改善预后。
Objective To evaluate the clinical effect of Xuebijing adjuvant treatment of sepsis. Methods 46 patients with sepsis treated at the same period were randomly divided into treatment group (n = 26) and control group (n = 20). Both groups were given routine treatment. On the basis of this, Xuebijing Injection was added to the observation group. The C-reactive protein (CRP), APACHEⅡscore and mortality were observed at admission and 7 days after treatment. Results After 7 days of treatment, the indexes of both groups were significantly improved compared with that of admission. The serum CRP level, APACHEⅡscore and mortality in the observation group were significantly lower than those in the control group (P <0.05). Results Xuebijing Injection can block the pathogenesis of sepsis and significantly reduce its mortality and improve prognosis.